News Post BioMarin Teams Use Genetic Expertise and Computational Tools to Target More Common Conditions
Press Release Patents Issued Covering Stable Tablet Formulation and Once Daily Dosing Regimen for Kuvan
Press Release BioMarin and Alliant Pharmaceuticals Announce North American Licensing Agreement for Orapred
Press Release BioMarin’s Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 “40 Under 40” Award from the San Francisco Business Times
Press Release BioMarin’s Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
Press Release BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
Press Release BioMarin Partners with Believe Limited for ‘Breaking Through!’ Musical Theater Intensive
Press Release BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis 2017 Congress
Press Release BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
Press Release BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
